Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Adagene Inc. Sponsored ADR stock logo
ADAG
Adagene
$3.77
-5.0%
$3.80
$1.30
$4.75
$178.90M0.59213,672 shs26,677 shs
Allogene Therapeutics, Inc. stock logo
ALLO
Allogene Therapeutics
$2.22
+2.1%
$2.30
$0.98
$4.46
$764.51M0.468.19 million shs3.58 million shs
CryoPort, Inc. stock logo
CYRX
CryoPort
$15.66
-0.2%
$10.97
$5.31
$16.04
$792.54M1.9504,647 shs212,943 shs
Design Therapeutics, Inc. stock logo
DSGN
Design Therapeutics
$10.75
+2.6%
$12.28
$3.33
$17.25
$665.82M1.63501,418 shs711,367 shs
The 7 Hottest IPOs On Wall Street’s 2026 Watchlist Cover

MarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Adagene Inc. Sponsored ADR stock logo
ADAG
Adagene
0.00%+5.87%+7.88%+34.12%+104.64%
Allogene Therapeutics, Inc. stock logo
ALLO
Allogene Therapeutics
0.00%+8.50%+1.88%-18.11%+86.27%
CryoPort, Inc. stock logo
CYRX
CryoPort
0.00%+12.07%+52.92%+91.11%+158.91%
Design Therapeutics, Inc. stock logo
DSGN
Design Therapeutics
0.00%-4.47%-22.94%+2.44%+180.97%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Adagene Inc. Sponsored ADR stock logo
ADAG
Adagene
$3.77
-5.0%
$3.80
$1.30
$4.75
$178.90M0.59213,672 shs26,677 shs
Allogene Therapeutics, Inc. stock logo
ALLO
Allogene Therapeutics
$2.22
+2.1%
$2.30
$0.98
$4.46
$764.51M0.468.19 million shs3.58 million shs
CryoPort, Inc. stock logo
CYRX
CryoPort
$15.66
-0.2%
$10.97
$5.31
$16.04
$792.54M1.9504,647 shs212,943 shs
Design Therapeutics, Inc. stock logo
DSGN
Design Therapeutics
$10.75
+2.6%
$12.28
$3.33
$17.25
$665.82M1.63501,418 shs711,367 shs
The 7 Hottest IPOs On Wall Street’s 2026 Watchlist Cover

MarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Adagene Inc. Sponsored ADR stock logo
ADAG
Adagene
0.00%+5.87%+7.88%+34.12%+104.64%
Allogene Therapeutics, Inc. stock logo
ALLO
Allogene Therapeutics
0.00%+8.50%+1.88%-18.11%+86.27%
CryoPort, Inc. stock logo
CYRX
CryoPort
0.00%+12.07%+52.92%+91.11%+158.91%
Design Therapeutics, Inc. stock logo
DSGN
Design Therapeutics
0.00%-4.47%-22.94%+2.44%+180.97%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Adagene Inc. Sponsored ADR stock logo
ADAG
Adagene
3.00
Buy$8.00112.15% Upside
Allogene Therapeutics, Inc. stock logo
ALLO
Allogene Therapeutics
2.69
Moderate Buy$8.52284.75% Upside
CryoPort, Inc. stock logo
CYRX
CryoPort
2.89
Moderate Buy$14.69-6.18% Downside
Design Therapeutics, Inc. stock logo
DSGN
Design Therapeutics
2.88
Moderate Buy$16.5053.49% Upside

Current Analyst Ratings Breakdown

Latest ADAG, CYRX, ALLO, and DSGN Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
5/20/2026
CryoPort, Inc. stock logo
CYRX
CryoPort
Boost Price TargetOverweight$15.00 ➝ $17.00
5/12/2026
Design Therapeutics, Inc. stock logo
DSGN
Design Therapeutics
Initiated CoverageOverweight
5/6/2026
CryoPort, Inc. stock logo
CYRX
CryoPort
UpgradeSell (D+)Hold (C-)
5/5/2026
CryoPort, Inc. stock logo
CYRX
CryoPort
Boost Price TargetBuy$11.00 ➝ $12.00
5/5/2026
CryoPort, Inc. stock logo
CYRX
CryoPort
Boost Price TargetBuy$15.00 ➝ $17.00
5/5/2026
CryoPort, Inc. stock logo
CYRX
CryoPort
Boost Price TargetBuy$13.00 ➝ $15.00
5/4/2026
Design Therapeutics, Inc. stock logo
DSGN
Design Therapeutics
Boost Price TargetOutperform$18.00 ➝ $21.00
5/1/2026
Allogene Therapeutics, Inc. stock logo
ALLO
Allogene Therapeutics
Reiterated RatingSell (D-)
4/29/2026
Design Therapeutics, Inc. stock logo
DSGN
Design Therapeutics
Reiterated RatingOverweight$20.00
4/20/2026
Adagene Inc. Sponsored ADR stock logo
ADAG
Adagene
Reiterated RatingSell (D-)
4/20/2026
Design Therapeutics, Inc. stock logo
DSGN
Design Therapeutics
Reiterated RatingSell (D-)
(Data available from 6/1/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Adagene Inc. Sponsored ADR stock logo
ADAG
Adagene
$7.67M23.30N/AN/A$0.75 per share5.03
Allogene Therapeutics, Inc. stock logo
ALLO
Allogene Therapeutics
$20K38,225.36N/AN/A$1.30 per share1.70
CryoPort, Inc. stock logo
CYRX
CryoPort
$176.18M4.48N/AN/A$9.19 per share1.70
Design Therapeutics, Inc. stock logo
DSGN
Design Therapeutics
N/AN/AN/AN/A$3.73 per shareN/A
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Adagene Inc. Sponsored ADR stock logo
ADAG
Adagene
-$17.61MN/AN/AN/AN/AN/AN/AN/AN/A
Allogene Therapeutics, Inc. stock logo
ALLO
Allogene Therapeutics
-$190.89M-$0.77N/AN/AN/AN/A-56.45%-40.36%8/12/2026 (Estimated)
CryoPort, Inc. stock logo
CYRX
CryoPort
$78.30M$1.3511.65N/AN/A41.57%-7.92%-4.79%8/4/2026 (Estimated)
Design Therapeutics, Inc. stock logo
DSGN
Design Therapeutics
-$69.79M-$1.20N/AN/AN/AN/A-33.07%-31.29%8/6/2026 (Estimated)

Latest ADAG, CYRX, ALLO, and DSGN Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/13/2026Q1 2026
Allogene Therapeutics, Inc. stock logo
ALLO
Allogene Therapeutics
-$0.19-$0.18+$0.01-$0.18$0.00 millionN/A
5/4/2026Q1 2026
CryoPort, Inc. stock logo
CYRX
CryoPort
-$0.20-$0.23-$0.03-$0.25$44.86 million$47.80 million
4/28/2026Q1 2026
Design Therapeutics, Inc. stock logo
DSGN
Design Therapeutics
-$0.36-$0.29+$0.07-$0.29N/AN/A
4/1/2026Q4 2025
Adagene Inc. Sponsored ADR stock logo
ADAG
Adagene
-$0.28-$0.0440+$0.2360-$0.0440$17.50 million$3.84 million
3/12/2026Q4 2025
Allogene Therapeutics, Inc. stock logo
ALLO
Allogene Therapeutics
-$0.25-$0.17+$0.08-$0.17$0.00 millionN/A
3/9/2026Q4 2025
Design Therapeutics, Inc. stock logo
DSGN
Design Therapeutics
-$0.38-$0.27+$0.11-$0.27N/AN/A
3/3/2026Q4 2025
CryoPort, Inc. stock logo
CYRX
CryoPort
-$0.19-$0.21-$0.02-$0.27$42.92 million$45.45 million
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
Adagene Inc. Sponsored ADR stock logo
ADAG
Adagene
N/AN/AN/AN/AN/A
Allogene Therapeutics, Inc. stock logo
ALLO
Allogene Therapeutics
N/AN/AN/AN/AN/A
CryoPort, Inc. stock logo
CYRX
CryoPort
N/AN/AN/AN/AN/A
Design Therapeutics, Inc. stock logo
DSGN
Design Therapeutics
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Adagene Inc. Sponsored ADR stock logo
ADAG
Adagene
0.03
3.07
3.07
Allogene Therapeutics, Inc. stock logo
ALLO
Allogene Therapeutics
N/A
9.65
9.65
CryoPort, Inc. stock logo
CYRX
CryoPort
N/A
2.09
2.00
Design Therapeutics, Inc. stock logo
DSGN
Design Therapeutics
N/A
22.28
22.28

Institutional Ownership

CompanyInstitutional Ownership
Adagene Inc. Sponsored ADR stock logo
ADAG
Adagene
9.51%
Allogene Therapeutics, Inc. stock logo
ALLO
Allogene Therapeutics
83.63%
CryoPort, Inc. stock logo
CYRX
CryoPort
92.90%
Design Therapeutics, Inc. stock logo
DSGN
Design Therapeutics
56.64%

Insider Ownership

CompanyInsider Ownership
Adagene Inc. Sponsored ADR stock logo
ADAG
Adagene
21.20%
Allogene Therapeutics, Inc. stock logo
ALLO
Allogene Therapeutics
13.20%
CryoPort, Inc. stock logo
CYRX
CryoPort
10.10%
Design Therapeutics, Inc. stock logo
DSGN
Design Therapeutics
17.10%
CompanyEmployeesShares OutstandingFree FloatOptionable
Adagene Inc. Sponsored ADR stock logo
ADAG
Adagene
26047.39 million37.34 millionNot Optionable
Allogene Therapeutics, Inc. stock logo
ALLO
Allogene Therapeutics
310345.15 million299.60 millionOptionable
CryoPort, Inc. stock logo
CYRX
CryoPort
1,18650.40 million45.31 millionOptionable
Design Therapeutics, Inc. stock logo
DSGN
Design Therapeutics
4062.46 million51.78 millionOptionable

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
Adagene stock logo

Adagene NASDAQ:ADAG

$3.77 -0.20 (-5.01%)
As of 01:02 PM Eastern
This is a fair market value price provided by Massive. Learn more.

Adagene Inc., a clinical stage biotechnology company, engages in the research, development, and production of monoclonal antibody drugs for cancers. The company's product candidates include ADG106, a human ligand-blocking agonistic anti- CD137 IgG4 monoclonal antibodies (mAbs) that is in Phase 1b/2 clinical trials for the treatment advanced solid tumors and non-Hodgkin's lymphoma; ADG126, a masked fully-human anti-CTLA-4 mAb that is in Phase 1 clinical trial for the treatment advanced/metastatic solid tumors; and ADG116, a human ligand-blocking anti-CTLA-4 mAb, which is in Phase 1b/2 clinical development for the treatment of advanced/metastatic solid tumors. It also offers ADG104, an anti-PD-L1 mAb that is in Phase 2 clinical development; ADG125, a novel anti-CSF-1R mAb, which is in Phase I clinical trial; ADG206, a masked, Fc engineered anti-CD137 agonistic POWERbody; ADG153, a masked anti-CD47 IgG1 SAFEbody, which is in preclinical for the treatment hematologic and solid tumors; ADG138, novel HER2xCD3 POWERbody, which is in preclinical for the treatment HER2-expressing solid tumors; and ADG152, a v POWERbody, which is in preclinical stage for the treatment off-tumor toxicities, as well as develops anti-CD28 bispecific POWERbody TCEs. The company was incorporated in 2011 and is headquartered in Suzhou, China.

Allogene Therapeutics stock logo

Allogene Therapeutics NASDAQ:ALLO

$2.22 +0.05 (+2.07%)
As of 01:04 PM Eastern
This is a fair market value price provided by Massive. Learn more.

Allogene Therapeutics, Inc., a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer. It develops, manufactures, and commercializes UCART19, an allogeneic chimeric antigen receptor (CAR) T cell product candidate for the treatment of pediatric and adult patients with R/R CD19 positive B-cell acute lymphoblastic leukemia (ALL). The company also develops cemacabtagene ansegedleucel, an engineered allogeneic CAR T cell product candidate that targets CD19 for the treatment of large B-cell lymphoma; and is in Phase 1b clinical trial for the treatment of chronic lymphocytic leukemia. In addition, it is developing ALLO-715, an allogeneic CAR T cell product candidate that is in a Phase 1 clinical trial for treating R/R multiple myeloma; ALLO-605, an allogeneic CAR T cell product candidate that is in a Phase I clinical trial for the treatment of multiple myeloma; ALLO-647, an anti-CD52 monoclonal antibody; CD70 to treat renal cell cancer; ALLO-316, an allogeneic CAR T cell product candidate that is in Phase 1 clinical trial for the treatment of advanced or metastatic RCC; ALLO-329 for the treatment of certain autoimmune diseases; DLL3 for the treatment of small cell lung cancer and other aggressive neuroendocrine tumors; and Claudin 18.2 for the treatment of gastric and pancreatic cancer. The company has license and collaboration agreements with Pfizer Inc.; Servier; Cellectis S.A.; and Notch Therapeutics Inc. It also has a strategic collaboration agreement with The University of Texas MD Anderson Cancer Center for the preclinical and clinical investigation of allogeneic CAR T cell product candidates; and a strategic partnership with Foresight Diagnostics to develop MRD-based In-Vitro Diagnostic for use in ALPHA3. The company was incorporated in 2017 and is headquartered in South San Francisco, California.

CryoPort stock logo

CryoPort NASDAQ:CYRX

$15.66 -0.04 (-0.22%)
As of 01:04 PM Eastern
This is a fair market value price provided by Massive. Learn more.

Cryoport, Inc. provides temperature-controlled supply chain solutions in biopharma/pharma, animal health, and human reproductive medicine markets in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. The company offers Cryoport Express Shippers; Cryoport ELITE -80°C Gene Therapy Shipper; Cryoport ELITE Cryosphere Shipper; Cryoport consulting services, including physical, thermal, and shipping qualifications of shipping systems and/or packaging to developing custom packaging solutions; and Cryoport bioservices, such as controlled temperature storage, fulfilment, kit production, secondary packaging, labelling of therapeutic products, and GMP raw materials storage services. It also provides CRYOGENE, an unparalleled solution that offers pre-clinical temperature-controlled biological materials management services comprising specimen storage, processing, collection, and retrieval; CRYOPD, a temperature-controlled logistics solution, which include temperature-controlled packaging and transport solutions from cryogenic temperature to controlled ambient; and IntegriCell services that comprise apheresis/leukapheresis collection, Cryoshuttle transportation, cryo-process optimization and processing services. In addition, the company offers MVE Biological Solutions' Fusion cryogenic system, a self-sustaining cryogenic freezer; MVE Biological Solutions' Vario cryogenic system, a cryogenic freezer system that supports temperatures between -20°C and -150°C; Cryoport Cryoshuttle provides clients with dedicated local transportation support; and Tec4Med. Further, it provides biological specimen cryopreservation storage and maintenance; archiving, monitoring, tracking, receipt, and delivery of samples; frozen biological specimens transportation; and incoming and outgoing biological specimens management; and short-term logistics and engineering consulting services. Cryoport, Inc. was founded in 1999 and is headquartered in Brentwood, Tennessee.

Design Therapeutics stock logo

Design Therapeutics NASDAQ:DSGN

$10.75 +0.27 (+2.58%)
As of 01:03 PM Eastern
This is a fair market value price provided by Massive. Learn more.

Design Therapeutics, Inc. a biopharmaceutical company, researches, designs, develops, and commercializes small molecule therapeutic drugs for the treatment of genetic diseases in the United States. The company utilizes its GeneTAC platform to design and develop therapeutic candidates for inherited diseases caused by nucleotide repeat expansion. Its lead product candidates for potentially disease-modifying treatment comprises Friedreich Ataxia, a monogenic, autosomal recessive, progressive multi-system disease that affects organ systems dependent on mitochondrial function that brings to neurological, cardiac, and metabolic dysfunction; Myotonic Dystrophy Type-1, a dominantly-inherited, monogenic progressive neuromuscular disease affecting skeletal muscle, heart, brain, and other organs; Fuchs Endothelial Corneal Dystrophy, a genetic eye disease characterized by bilateral degeneration of corneal endothelial cells and progressive loss of vision; and Huntington's Disease, a dominantly inherited, monogenic neurodegenerative disease characterized by movement, cognitive, and psychiatric disorders. Design Therapeutics, Inc. was incorporated in 2017 and is headquartered in Carlsbad, California.